Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Novartis Pharmaceuticals
Femme et Homme Max 99 ans
Novartis Pharmaceuticals UK Ltd
MAJ Il y a 5 ans
A twelve week, randomized, double-blind, parallel-group multicentre study to evaluate the efficacy and safety of the combination of aliskiren/ramipril/amlodipine (300/10/10mg), compared to the combinations of ramipril/amlodipine (10/10mg) and aliskiren/amlodipine (300/10mg) in patients with essential hypertension and metabolic syndrome not adequately responsive to amlodipine 10mg
The primary objectives of this study are: 1. To demonstrate that the combination of aliskiren / ramipril / amlodipine (300/10/10 mg) has superior efficacy compared to the combinations of ramipril / am...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharmaceuticals UK Limited (UK)
MAJ Il y a 5 ans
Combination therapy of Visudyne, Minocycline, Dexamethasone and Ranibizumab (VIMDER) for the treatment of subfoveal choroidal neovascularisation (CNV)
Not provided at time of registration
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharmaceuticals
MAJ Il y a 5 ans
Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1)
1. Determine whether RAD001, administrated orally daily on a continuous dosing schedule might: a. Increases time to disease progression (TTP) based on volumetric MRI measurements in children and adul...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharmaceuticals
MAJ Il y a 5 ans
Phase II Efficacy Study Looking at a Single-dose of One of Three Dose Levels of AIN457 in Patients With Chronic Plaque-type Psoriasis
This is an exploratory, 4 arm, parallel group, placebo-controlled study comparing three doses of AIN457 to placebo. Subjects with a diagnosis of moderate to severe chronic plaque psoriasis...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharmaceuticals
MAJ Il y a 5 ans
Combination of Benazepril Plus Hydrochlorothiazide in Chinese Patients With Mild to Moderate Essential Hypertension
This study will evaluate efficacy and safety data for benazepril/hydrochlorothiazide in adult Chinese patients with mild to moderate essential hypertension. Patients whose blood pressure i...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharmaceuticals Corporation
MAJ Il y a 5 ans
A study of the Palatability and Tolerability of Exjade Taken with Meals, with Different Liquids or Crushed and Added to Food
To evaluate the palatability of Exjade administered with meals, added to different liquids and crushed and added to food
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharmaceuticals Corporation
MAJ Il y a 5 ans
A study to compare two different forms of the same medicine (deferasirox tablet that is dissolved in liquid form vs. deferasirox film-coated tablet form) to see how much of each type of medicine ends up in the blood
Evaluate the PK comparability of deferasirox with a reduced dosage strenght of the Film-coated tablet(FCT) vs. the dispersible tablets (DT) in healthy subjects under fasted conditions.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharmaceuticals UK Ltd
MAJ Il y a 5 ans
A multi-centre, randomised, double blind, parallel group study to investigate the efficacy and tolerability of treatment (24 weeks double blind phase followed by open-label extension) with either vildagliptin ( Galvus) or placebo combined with metformin in achieving optimal glycaemic control in older patients with type 2 diabetes
To demonstrate superior HbA1c control rates (where control is defined as HbA1c= or <6.5%) after 24 weeks treatment in subjects given vildagliptin added to metformin compared to those given placebo add...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharmaceuticals UK Ltd
MAJ Il y a 5 ans
A phase II, open-label, multicentre, 12 month study to evaluate the efficacy and safety of ranibizumab (0.5 mg) in patients with choroidal neovascularization secondary to pathological myopia (PM)
To provide safety and efficacy data in patients with CNV secondary to PM using a guided individualised as-needed (PRN) dosage schedule. The mean change in best-corrected visual acuity (BCVA) from Ba...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme Max 99 ans
Novartis Pharmaceuticals UK Ltd
MAJ Il y a 5 ans
Neoadjuvant hormone therapy for postmenopausal women with ER and/or PgR positive primary breast cancer: A multi-center study to determine the optimum length of treatment with Femara (letrozole 2.5mg daily) on tumour regression to permit breast conserving surgery
To determine the optimal treatment duration with letrozole (2.5 mg daily) preoperatively in order to permit breast conserving surgery in patients with early breast cancer, who are initially not suitab...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4
5
6
7
Suivant